Canlyniadau Chwilio - Aaron N. Hata

Mireinio'r Canlyniadau
  1. 1
    Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights

    Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights gan Catherine B. Meador, Aaron N. Hata

    Cyhoeddwyd 2020
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer

    Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer gan Heidie Frisco Cabanos, Aaron N. Hata

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics

    The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics gan Aaron N. Hata, Jeffrey A. Engelman, Anthony C. Faber

    Cyhoeddwyd 2015
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Stitchr: stitching coding TCR nucleotide sequences from V/J/CDR3 information

    Stitchr: stitching coding TCR nucleotide sequences from V/J/CDR3 information gan James Heather, Matthew Spindler, Marta Herrero Alonso, Yifang Shui, David G. Millar, David S. Johnson, Mark Cobbold, Aaron N. Hata

    Cyhoeddwyd 2022
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Colon Carcinoma Cell Growth Is Associated with Prostaglandin E2/EP4 Receptor-evoked ERK Activation

    Colon Carcinoma Cell Growth Is Associated with Prostaglandin E2/EP4 Receptor-evoked ERK Activation gan Ambra Pozzi, Xuexian Yan, Ines Macias‐Perez, Shouzuo Wei, Aaron N. Hata, Richard Breyer, Jason D. Morrow, Jorge H. Capdevila

    Cyhoeddwyd 2004
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Fatty acids and cancer-amplified ZDHHC19 promote STAT3 activation through S-palmitoylation

    Fatty acids and cancer-amplified ZDHHC19 promote STAT3 activation through S-palmitoylation gan Jixiao Niu, Yang Sun, Baoen Chen, Baohui Zheng, Gopala K. Jarugumilli, Sarah R. Walker, Aaron N. Hata, Mari Mino‐Kenudson, David A. Frank, Xu Wu

    Cyhoeddwyd 2019
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies

    Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies gan Clemens Grassberger, David M. McClatchy, Changran Geng, Sophia C. Kamran, Florian J. Fintelmann, Yosef E. Maruvka, Zofia Piotrowska, Henning Willers, Lecia V. Sequist, Aaron N. Hata, Harald Paganetti

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Unprocessed genomic uracil as a source of DNA replication stress in cancer cells

    Unprocessed genomic uracil as a source of DNA replication stress in cancer cells gan Sneha Saxena, Christopher S. Nabel, Turner W. Seay, Parasvi S. Patel, Ajinkya S. Kawale, Caroline R. Crosby, Helene Tigro, Eugene Oh, Matthew G. Vander Heiden, Aaron N. Hata, Zucai Suo, Lee Zou

    Cyhoeddwyd 2024
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases

    Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases gan Hironori Uruga, Emine Bozkurtlar, Tiffany G. Huynh, Alona Muzikansky, Yasushi Goto, María Gomez‐Caraballo, Aaron N. Hata, Justin F. Gainor, Eugene J. Mark, Jeffrey A. Engelman, Michael Lanuti, Mari Mino‐Kenudson

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction

    Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction gan Kyle Vaccaro, Juliet Allen, Troy W. Whitfield, Asaf Maoz, Sarah Reeves, José Velarde, Dian Yang, Anna Meglan, Juliano Ribeiro, Jasmine Blandin, Nicole Phan, George W. Bell, Aaron N. Hata, Kipp Weiskopf

    Cyhoeddwyd 2024
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity

    Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity gan Lynnette Marcar, Kankana Bardhan, Liliana Gheorghiu, Patrick Dinkelborg, Heike N. Pfäffle, Qi Liu, Meng Wang, Zofia Piotrowska, Lecia V. Sequist, Kerstin Borgmann, Jeffrey Settleman, Jeffrey A. Engelman, Aaron N. Hata, Henning Willers

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers

    Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers gan Aaron N. Hata, Alan T. Yeo, Anthony C. Faber, Eugene Lifshits, Zhao Chen, Katherine A. Cheng, Zandra E. Walton, Kristopher A. Sarosiek, Anthony Letai, Rebecca S. Heist, Mari Mino‐Kenudson, Kwok‐Kin Wong, Jeffrey A. Engelman

    Cyhoeddwyd 2014
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment

    Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment gan Tiffany G. Huynh, Vicente Morales‐Oyarvide, Meghan Campo, Justin F. Gainor, Emine Bozkurtlar, Hironori Uruga, Ling Zhao, María Gomez‐Caraballo, Aaron N. Hata, Eugene J. Mark, Michael Lanuti, Jeffrey A. Engelman, Mari Mino‐Kenudson

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    Treatment with Next-Generation ALK Inhibitors Fuels Plasma <i>ALK</i> Mutation Diversity

    Treatment with Next-Generation ALK Inhibitors Fuels Plasma <i>ALK</i> Mutation Diversity gan Ibiayi Dagogo‐Jack, Marguerite Rooney, W. Marston Linehan, Rebecca J. Nagy, Beow Y. Yeap, Harper Hubbeling, Emily Chin, Jennifer Ackil, Anna F. Farago, Aaron N. Hata, Jochen K. Lennerz, Justin F. Gainor, Richard B. Lanman, Alice T. Shaw

    Cyhoeddwyd 2019
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC

    MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC gan Naoki Haratake, Hiroki Ozawa, Yoshihiro Morimoto, Nami Yamashita, Tatsuaki Daimon, Atrayee Bhattacharya, Keyi Wang, Ayako Nakashoji, Hideko Isozaki, Mototsugu Shimokawa, Chie Kikutake, Mikita Suyama, Asato Hashinokuchi, Kazuki Takada, Tomoyoshi Takenaka, Tomoharu Yoshizumi, Tetsuya Mitsudomi, Aaron N. Hata, Donald Küfe

    Cyhoeddwyd 2023
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor

    A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor gan Ibiayi Dagogo‐Jack, Philicia Moonsamy, Justin F. Gainor, Jochen K. Lennerz, Zofia Piotrowska, W. Marston Linehan, Inga T. Lennes, Lecia V. Sequist, Alice T. Shaw, Kelly Goodwin, Sara E. Stevens, Andrew Do, Subba R. Digumarthy, Kristin S. Price, Alona Muzikansky, Aaron N. Hata, Rebecca S. Heist

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in <i>BRAF-</i> Mutant Melanoma

    TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in <i>BRAF-</i> Mutant Melanoma gan Ryan B. Corcoran, S. Michael Rothenberg, Aaron N. Hata, Anthony C. Faber, Adriano Piris, Rosalynn M. Nazarian, Ronald D. Brown, Jason T. Godfrey, Daniel Winokur, John R. Walsh, Mari Mino‐Kenudson, Shyamala Maheswaran, Jeffrey Settleman, Jennifer A. Wargo, Keith T. Flaherty, Daniel A. Haber, Jeffrey A. Engelman

    Cyhoeddwyd 2013
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    Targeting TREX1 induces innate immune response in drug-resistant Small Cell Lung Cancer

    Targeting TREX1 induces innate immune response in drug-resistant Small Cell Lung Cancer gan Takahiko Murayama, Navin R. Mahadevan, Catherine B. Meador, Elena Ivanova, Yuqiao Pan, Erik H. Knelson, Tetsuo Tani, Jun Nakayama, Xueying Ma, Tran C. Thai, Yin P. Hung, William Kim, Hideo Watanabe, Kathy Q. Cai, Aaron N. Hata, Cloud P. Paweletz, David A. Barbie, Israel Cañadas

    Cyhoeddwyd 2024
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells

    Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells gan Moiez Ali, Min Lu, Hazel X. Ang, Ryan S. Soderquist, Christine E. Eyler, Haley M. Hutchinson, Carolyn Glass, Christopher F. Bassil, Omar Lopez, D. Lucas Kerr, Christina J. Falcon, Helena A. Yu, Aaron N. Hata, Collin M. Blakely, Caroline E. McCoach, Trever G. Bivona, Kris C. Wood

    Cyhoeddwyd 2022
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  20. 20
    Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in <i>ROS1</i>-Positive Non–Small-Cell Lung Cancer

    Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in <i>ROS1</i>-Positive Non–Small-Cell Lung Cancer gan Justin F. Gainor, Diane Tseng, Satoshi Yoda, Ibiayi Dagogo‐Jack, Luc Friboulet, W. Marston Linehan, Harper Hubbeling, Leila Dardaei, Anna F. Farago, Katherine R. Schultz, Lorin A. Ferris, Zofia Piotrowska, James C.H. Hardwick, Donghui Huang, Mari Mino‐Kenudson, A. John Iafrate, Aaron N. Hata, Beow Y. Yeap, Alice T. Shaw

    Cyhoeddwyd 2017
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: